Single-dose Study Testing Rivaroxaban Granules for Oral Suspension Formulation in Children From 2 Months to 12 Years With Previous Thrombosis

Trial Profile

Single-dose Study Testing Rivaroxaban Granules for Oral Suspension Formulation in Children From 2 Months to 12 Years With Previous Thrombosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Thrombosis
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 05 Apr 2017 Planned number of patients changed from 48 to 58.
    • 15 Mar 2017 Planned End Date changed from 1 Dec 2017 to 30 Dec 2017.
    • 15 Mar 2017 Planned primary completion date changed from 1 Dec 2017 to 28 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top